Lupus-like syndrome attributable to anti-tumor necrosis factor α therapy in 14 patients during an 8-year period at mayo clinic

Mayo Clinic Proceedings

Volumn 84, Issue 11, 2009, Pages 979-984

  Wetter, David A ^a   Davis, Mark D P ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CORTICOSTEROID; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; INFLIXIMAB; LUPUS ANTICOAGULANT; METHOTREXATE; PREDNISONE;

ADULT; ARTICLE; ATTRIBUTABLE RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENERALIZED EDEMA; HEMATOLOGIC DISEASE; HUMAN; HYPERSENSITIVITY; IMMUNOFLUORESCENCE MICROSCOPY; INFLAMMATION; LUPUS LIKE SYNDROME; MALE; MOUTH ULCER; ONSET AGE; OUTCOME ASSESSMENT; PHOTOSENSITIVITY; RASH; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT DURATION; UNITED STATES; VISUAL IMPAIRMENT;

ACADEMIC MEDICAL CENTERS; AGE DISTRIBUTION; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MINNESOTA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SAMPLING STUDIES; SEX DISTRIBUTION; SYNDROME; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 71449111969     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.11.979     Document Type: Article

References (22)

1. Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther. 2008;10(1):202. Epub 2008 Jan 23. (Pubitemid 352044828)
2. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus. 2005;14(12):931-937. (Pubitemid 43088266)
3. Mongey AB, Hess EV. Drug insight: autoimmune effects of medications: what's new? Nat Clin Pract Rheumatol. 2008;4(3):136-144.
4. Cush JJ. Unusual toxicities with TNF inhibition: heart failure and druginduced lupus. Clin Exp Rheumatol. 2004;22(5)(suppl 35):S141-S147.
5. Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P. Autoimmunity and anti-TNF-α agents. Ann N Y Acad Sci. 2005;1051:559-569.
6. De Bandt M. Lessons for lupus from tumour necrosis factor blockade. Lupus. 2006;15(11):762-767.
7. Caramaschi P, Biasi D, Colombatti M, et al. Anti-TNFα therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int. 2006 Jan;26(3):209-214. Epub 2004 Dec 31. (Pubitemid 41830977)
8. Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther. 2004;6(6):R535-R543. Epub 2004 Sep 23.
9. Poulalhon N, Begon E, Lebbé C, et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol. 2007;156(2):329-336. (Pubitemid 46095962)
10. Callen JP. Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg. 2007;26(1):6-14. (Pubitemid 46349778)
11. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat. 2004;15(5):280-294. (Pubitemid 39423287)
12. Lebwohl M, Bagel J, Gelfand JM, et al. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol. 2008 Jan;58(1):94-105. Epub 2007 Nov 5. (Pubitemid 350302037)
13. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86(4):242-251. (Pubitemid 47067483)
14. Sarzi-Puttini P, Atzeni F, Capsoni F, Lubrano E, Doria A. Druginduced lupus erythematosus [published retraction appears in Autoimmunity. 2008;41(3):241]. Autoimmunity. 2005;38(7):507-518.
15. De Bandt M, Sibilia J, Le Loët X, et al; Club Rhumatismes et Inflammation. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7(3):R545-R551. Epub 2005 Mar 1.
16. Vasoo S. Drug-induced lupus: an update. Lupus. 2006;15(11):757-761.
17. Benucci M, Li Gobbi F, Fossi F, Manfredi M, Del Rosso A. Drug-induced lupus after treatment with infliximab in rheumatoid arthritis. J Clin Rheumatol. 2005;11(1):47-49. (Pubitemid 40223880)
18. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum. 1997;40(9):1725.
19. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2004;126(1):19-31.
20. Costner MI, Sontheimer RD, Provost TT. Lupus erythematosus. In: Sontheimer RD, Provost TT, eds. Cutaneous Manifestations of Rheumatic Diseases. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:15-64.
21. Page AV, Liles WC. Tumor necrosis factor-α inhibitor-induced lupuslike syndrome presenting as fever of unknown origin in a liver transplant recipient: case report and concise review of the literature. Transplant Proc. 2008;40(5):1768-1770.
22. Delgado-Rodríguez M, Llorca J. Bias. J Epidemiol Community Health. 2004;58(8):635-641.